Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Multiferon high-dose versus low-dose plus ribavirin in genotype 1 chronic hepatitis C after incomplete response to pegylated interferon
2006-000524-14Phase 2Terminated
- Sponsor
- ViraNative
- Start
- Feb 2006
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of interferon alfa and ribavirin in hepatitis C virus infection (2 arms), sponsored by ViraNative. Primary endpoints: Efficacy comparison of low-dose versus high-dose Multiferon plus ribavirin, Safety and tolerability and 1 more. Started Feb 2006; status: terminated.
02
Drugs
interferon alfaribavirin
03
Conditions
hepatitis C virus infection
Beyond the preview
Go deeper on 2006-000524-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-000524-14.